The Hunter Williams Podcast Do GLP-1s Prevent Cancer?
Nov 28, 2025
A groundbreaking study reveals GLP-1 agonists can reduce overall cancer risk by 17%. Specific risks drop significantly: for ovarian cancer, there's a 47% reduction, and a 31% decline in brain tumors. The podcast explores how these medications may reduce inflammation and improve insulin sensitivity, linking obesity to 13 types of cancer. It also discusses evidence from weight loss interventions and emphasizes the need for more research into GLP-1s' potential in cancer prevention.
AI Snips
Chapters
Transcript
Episode notes
Large Study Shows Lower Cancer Rates
- A large observational study of 86,632 people found GLP-1 use linked to a 17% lower overall cancer incidence. Specific drops included 25% less endometrial and 47% less ovarian cancer among users.
Obesity Is A Major Cancer Driver
- Obesity links to at least 13 cancer types and accounts for about 40% of U.S. cancer diagnoses. This positions metabolic health as the second leading preventable cause of cancer after tobacco.
How Obesity Promotes Tumor Growth
- Mechanisms tying obesity to cancer include altered estrogens, high insulin/IGF-1 signaling, and chronic inflammation from fat tissue. These create environments that promote tumor growth and suppress immune surveillance.